Loading…
← CockpitCompetitor Analysis › PBH Prestige Consumer Healthcare IncOpen in the cockpit ↗

Prestige Consumer Healthcare IncPBHCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Owns and markets a portfolio of over-the-counter consumer health and personal-care brands sold at retail.

Momentum strong 66
Mkt cap
$2.40B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$30.1M
20-day average traded
Fwd P/E
10.6×
forward earnings
ROIC−WACC
-0.4 pp
WACC 6.1%
Hurdle
-1 pp
Req g minus delivered
Next earnings
78 days
4 Feb 2027
Close · USD$50.62
1D+5.0%
1W+14.6%
1M+2.5%
3M+0.2%
6M+7.3%
YTD-17.9%
1Y-14.2%
ATR %4.1%
Beta0.39
52w lowhigh28.8% off high

What Prestige Consumer Healthcare does

Owns and markets a portfolio of over-the-counter consumer health and personal-care brands sold at retail.

Buys established over-the-counter brands that larger companies treat as too small, outsources almost all manufacturing to contract makers, and spends on advertising to hold shelf space. Walmart is its largest customer. Sales are mostly in North America, with smaller bases in Australia and elsewhere.

Products and services

  • Monistat
  • Clear Eyes / Compound W
  • BC/Goody's powders, Dramamine

Customers

  • Mass retailers, drugstores, grocery chains

Where it sits in the supply chain

  • Consumer health products
  • OTC brand ownership/marketing
  • Retail/pharmacy distribution

What could go right

  • Bolt-on brand acquisitions
  • Pricing power on trusted OTC brands

What could go wrong

  • Retailer private-label competition
  • Input-cost/tariff pressure

Moat: narrow (brand, distribution). Long-established OTC brand names hold trusted shelf space that is hard for new entrants to win.

Headquarters: Tarrytown, New York, US · Founded: 1996 · Employees: 890

Named competitors

Prestige Consumer Healthcare at a glance

Size Prestige Consumer Healthcare (PBH) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $2.40B, the 1666th largest of 3,085 United States companies the cockpit tracks. Shares closed at $50.62 on 18 Nov 2026.

Performance Over six months the shares gained 7.3%, against -11.5% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 5.1% over the last twelve months (peer median +4.2%); the operating margin is 24.9% (peer median 9.1%).

Valuation It trades at 10.6× forward earnings against a peer median of 27.3× (2nd cheapest of 15).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -1 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.4 points below its cost of capital (6.1% WACC).

Short interest Short interest is 8.9% of the free float (30 Oct 2026).

Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026PBH 105Peer median 89
Six months, rebased to 100: Prestige Consumer Healthcare against the median of its 20 peers (local-currency closes).

Prestige Consumer Healthcare financials

Reported figures in USD; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.17B$1.09B$1.14B$1.13B$1.13B
Revenue growth—-4%+1%0%—
Gross profit$587M$575M$613M$602M$600M
EBITDA$328M$341M$379M$373M$387M
Net income$155M$190M$215M$209M-$82.3M
Free cash flow$214M$246M$243M$239M$222M
Capital expenditure$15.6M$11.2M$8.22M$9.55M$7.78M
Total debt$2.13B$1.05B$1.04B$1.14B$1.37B

Quarterly statements and history in the cockpit →

Prestige Consumer Healthcare competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%369621620013NAMS000250PRGOALMRGC301080301301603858IDYA600518APLLTD600267BIOA-B300199PBH6-month return →1-month return →
Up and to the right = strong over both horizons. Prestige Consumer Healthcare is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%+150%25×50×75×369621620013PRGOALM301080301301600267BIOA-B300199300558214450PBHRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Prestige Consumer Healthcare is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%+100%0%50%100%36960013PRGOALM301080301301603858APLLTD600867600267BIOA-B300199300558214450PBHGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Prestige Consumer Healthcare is the large dot.

Prestige Consumer Healthcare competitors and peer comparison

Head to head with its named competitors (PBH vs KVUE vs HLN.L vs CHD)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Prestige Consumer Healthcare PBH$2.40B+7%+5%25%10.6×2.3%
Kenvue KVUEn/a+12%n/an/an/an/a
Haleon HLN.L$39.6B0%+1%23%16.4×5.2%
Church & Dwight CHD$26.4B+16%+2%18%28.1×7.7%
Reckitt Benckiser RKT.L$47.5B+22%-2%28%16.7×2.1%

How Prestige Consumer Healthcare compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Prestige Consumer Healthcare against its 20 peers (data as of 18 Nov 2026)
MeasurePBHPeer medianRank in peer set
1-month return+2.5%-5.5%3rd highest of 21
6-month return+7.3%-11.5%7th highest of 21
Distance from 52-week high-28.8%-33.1%11th highest of 21
Revenue growth (TTM)+5.1%+4.2%10th highest of 20
Operating margin24.9%9.1%3rd highest of 19
Forward P/E10.6×27.3×2nd cheapest of 15
Growth the price implies (Req g, 7 yrs)2.3%18.7%5th least demanding of 15
Growth delivered (Del g)+2.9%+6.5%5th lowest of 15
Hurdle (Req g minus delivered)-0.6 pp+6.3 pp5th least demanding of 15
ROIC minus cost of capital-0.4 pp-2.2 pp6th highest of 15
EV / EBITDA13.7×9.5×2nd most expensive of 5
Net debt / EBITDA6.3×-0.1×most indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Prestige Consumer Healthcare PBHUnited States$2.40B+7%+5%25%10.6×2.3%+2.9%
InSilico Medicine Cayman TopCo 3696.HKHong Kong$2.40B-33%+153%-7%85.2×37.9%+22.9%
Keymed Biosciences 2162.HKHong Kong$2.39B+7%0%-73%18.2×n/an/a
HUTCHMED (China) 0013.HKHong Kong$2.38B+14%-9%-6%35.9×47.0%+19.3%
NewAmsterdam Pharma NAMSUnited States$2.37B-45%-26%-900%n/an/an/a
Sam Chun Dang Pharm 000250.KSSouth Korea$2.36B-66%+23%7%n/an/an/a
Perrigo PRGOUnited States$2.35B+52%-4%5%6.7×14.1%+0.8%
Almirall ALM.MCSpain$2.46B-13%+24%8%27.1×6.1%+6.5%
Regencell Bioscience RGCUnited States$2.33B-83%n/an/an/an/an/a
Acrobiosystems 301080.SZChina$2.31B+65%+29%17%55.2×41.3%+27.7%
Yili Chuanning Biotechnology 301301.SZChina$2.49B-24%-14%16%27.6×3.4%+4.8%
Shandong Buchang Pharmaceuticals 603858.SSChina$2.25B-7%+4%10%n/a-2.5%-5.8%
IDEAYA Biosciences IDYAUnited States$2.56B-11%-83%-1,267%n/an/an/a
Kangmei Pharmaceutical 600518.SSChina$2.61B-21%-6%-7%n/an/an/a
Alembic Pharmaceuticals APLLTD.NSIndia$2.20B+39%+20%12%25.0×26.7%+6.5%
Tonghua Dongbao Pharmaceutical 600867.SSChina$2.19B-12%+18%n/a25.4×0.9%+0.3%
Zhejiang Hisun Pharmaceutical 600267.SSChina$2.19B+14%-7%15%15.0×-9.7%-1.5%
BioArctic BIOA-B.STSweden$2.66B-9%-46%22%52.9×25.5%+100.1%
Hybio Pharmaceutical 300199.SZChina$2.68B-8%+70%31%44.7×37.4%+6.1%
Betta Pharmaceuticals 300558.SZChina$2.70B-15%+16%11%38.0×23.2%+14.0%
PharmaResearch 214450.KSSouth Korea$2.10B-24%+29%37%15.4×-11.0%+37.6%

Questions

Who are Prestige Consumer Healthcare's main competitors?
Named competitors: Kenvue (KVUE), Haleon (HLN.L), Church & Dwight (CHD), Reckitt Benckiser (RKT.L). The cockpit's measured peer set (industry) also includes InSilico Medicine Cayman TopCo (3696.HK), Keymed Biosciences (2162.HK), HUTCHMED (China) (0013.HK), NewAmsterdam Pharma (NAMS), Sam Chun Dang Pharm (000250.KS), Perrigo (PRGO).
Is Prestige Consumer Healthcare expensive compared with its peers?
On forward p/e it trades at 10.6× against a peer median of 27.3×, 2nd cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -1 pp: the price already allows for a slowdown.
How has Prestige Consumer Healthcare stock performed?
Over six months to 18 Nov 2026 the shares returned +7.3% against -11.5% for the median peer; over one year -14.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.